Skip to main content

Advertisement

Table 1 Clinical characteristic of patients with rheumatoid arthritis

From: Suppressed diversity of survivin splicing in active rheumatoid arthritis

  Cohort (n = 67) Rituximab-treated group (n = 23)
Age (years) 56.6 (24–79) 59.4 (29–79)
Female/male 65/2 21/2
Disease duration (years) 10.2 (1–40) 13.1 (2–33)
RF positive (%) 83.6 96.0
ACPA positive (%) 71.7 83.0
DAS28 3.86 (1.38–6.77) 5.89 (4.6–6.8)
Methotrexate (n) 55 (82.1 %) 18 (78.3 %)
Dose (mg/week) 18.2 (7.5–25) 18.0 (10–25)
Anti-TNFα 10 (14.9 %) 0
Rituximab 13 (19.4 %) 9 (39.1 %)
Anti-IL-6R 2 (3.0 %) 0
CTLA4 1 (1.5 %) 0
Serum survivin (ng/ml) 18.5 (0.02–306.21) 2.07(0.10–14.9)
  1. Values are mean and minimum and maximum are shown
  2. ACPA antibodies against cyclic citrullinated peptides, CTLA4 cytotoxic T lymphocyte associated protein, DAS28 Disease Activity Score based on the evaluation of 28 joints, IL-6R interleukin 6 receptor, RF rheumatoid factor, TNFα tumour necrosis factor alpha